The stock of Spyre Therapeutics Inc (SYRE) has seen a -18.21% decrease in the past week, with a 0.00% drop in the past month, and a -15.24% decrease in the past quarter. The volatility ratio for the week is 5.46%, and the volatility levels for the past 30 days are at 4.22% for SYRE. The simple moving average for the past 20 days is -6.39% for SYRE’s stock, with a -33.30% simple moving average for the past 200 days.
Is It Worth Investing in Spyre Therapeutics Inc (NASDAQ: SYRE) Right Now?
The 36-month beta value for SYRE is also noteworthy at 2.74. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for SYRE is 51.32M, and at present, short sellers hold a 23.56% of that float. The average trading volume of SYRE on June 18, 2025 was 623.45K shares.
SYRE) stock’s latest price update
The stock price of Spyre Therapeutics Inc (NASDAQ: SYRE) has dropped by -11.64 compared to previous close of 17.18. Despite this, the company has seen a fall of -18.21% in its stock price over the last five trading days. prnewswire.com reported 2025-06-17 that SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more than 3-fold greater than first-generation anti-TL1A antibodies SKYLINE-UC platform study evaluating three optimized monotherapies and three potentially paradigm-changing combinations in ulcerative colitis, initiated in May 2025 SKYWAY-RD basket study evaluating SPY072 in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) announced, with initiation expected in Q3 2025 Management to host a webcast and conference call today at 8:00 a.m. ET WALTHAM, Mass.
Analysts’ Opinion of SYRE
Many brokerage firms have already submitted their reports for SYRE stocks, with Leerink Partners repeating the rating for SYRE by listing it as a “Outperform.” The predicted price for SYRE in the upcoming period, according to Leerink Partners is $45 based on the research report published on April 08, 2025 of the current year 2025.
Wolfe Research, on the other hand, stated in their research note that they expect to see SYRE reach a price target of $27. The rating they have provided for SYRE stocks is “Outperform” according to the report published on March 18th, 2025.
Wedbush gave a rating of “Outperform” to SYRE, setting the target price at $45 in the report published on September 04th of the previous year.
SYRE Trading at 2.89% from the 50-Day Moving Average
After a stumble in the market that brought SYRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.30% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SYRE starting from Albers Jeffrey W., who sale 6,700 shares at the price of $36.76 back on Nov 06 ’24. After this action, Albers Jeffrey W. now owns 27,360 shares of Spyre Therapeutics Inc, valued at $246,313 using the latest closing price.
Albers Jeffrey W., the Director of Spyre Therapeutics Inc, sale 300 shares at $36.43 during a trade that took place back on Oct 25 ’24, which means that Albers Jeffrey W. is holding 34,060 shares at $10,929 based on the most recent closing price.
Stock Fundamentals for SYRE
The total capital return value is set at -0.43. Equity return is now at value -50.47, with -30.31 for asset returns.
Currently, EBITDA for the company is -207.97 million with net debt to EBITDA at 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.06.
Conclusion
In summary, Spyre Therapeutics Inc (SYRE) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
